Abstract:
General Background: Myocardial infarction (MI) remains a leading cause of mortality worldwide, with early diagnosis being crucial for effective intervention. Specific Background: Biomarkers such as Chemerin, Creatine Kinase (CK), and Lactate Dehydrogenase (LDH) have been implicated in inflammatory responses and vascular dysfunction associated with MI. Knowledge Gap: Despite existing studies on these biomarkers, their combined diagnostic potential and correlation with cardiovascular risk factors remain underexplored. Aims: This study investigates the relationship between Chemerin, CK, and LDH levels in MI patients, alongside other risk factors such as body mass index (BMI) and smoking, to assess their role as potential early diagnostic indicators. Results: A total of 70 samples (50 MI patients, 20 controls) were analyzed at Azadi Educational Hospital, Kirkuk, from November 2023 to March 2024. The study found significantly elevated levels of Chemerin, CK, and LDH (P < 0.05) in MI patients compared to controls, indicating their involvement in inflammation and myocardial damage. Novelty: This study provides evidence that these biomarkers, particularly Chemerin, may serve as predictive indicators for MI risk, offering an alternative approach for early detection. Implications: The findings highlight the potential of biomarker-based screening in clinical settings and emphasize the importance of lifestyle modifications to mitigate MI risks and complications.
Highlights:
Biomarkers play a crucial role in myocardial infarction diagnosis.
Chemerin, CK, and LDH significantly elevated in MI patients (P < 0.05).
Potential biomarkers for early MI detection and risk assessment.
Keywords: Chemerin; Creatine Kinase; lactate dehydrogenase; Myocardial Infarction; Smoking.
References
M. Bilici, M. Ture, and H. Balik, "Myocardial infarction in children," Myocardial Infarction, p. 101, Jan. 2019. https://www.intechopen.com/chapters/60068 .
Board on the Health of Select Populations, Committee on Social Security Cardiovascular Disability Criteria, Cardiovascular disability: updating the Social Security listings. National Academies Press, Nov. 2010. https://www.ncbi.nlm.nih.gov/books/NBK209964/
D. Jenča, V. Melenovský, J. Stehlik, V. Staněk, J. Kettner, J. Kautzner, V. Adámková, and P. Wohlfahrt, "Heart failure after myocardial infarction: incidence and predictors," ESC Heart Failure, vol. 8, no. 1, pp. 222–237, Feb. 2021. https://doi.org/10.1002/ehf2.13144.
B. Boden-Albala and R. L. Sacco, "Lifestyle factors and stroke risk: exercise, alcohol, diet, obesity, smoking, drug use, and stress," Current Atherosclerosis Reports, vol. 2, no. 2, pp. 160–166, Mar. 2000. https://doi.org/10.1007/s11883-000-0111-3.
L. F. Hamm, N. K. Wenger, R. Arena, D. E. Forman, C. J. Lavie, T. D. Miller, and R. J. Thomas, "Cardiac rehabilitation and cardiovascular disability: role in assessment and improving functional capacity: a position statement from the American Association of Cardiovascular and Pulmonary Rehabilitation," Journal of Cardiopulmonary Rehabilitation and Prevention, vol. 33, no. 1, pp. 1–1, Jan. 2013. https://doi.org/10.1097/HCR.0b013e31827aad9e .
K. Sato, H. Yoshizawa, T. Seki, R. Shirai, T. Yamashita, T. Okano, K. Shibata, M. J. Wakamatsu, Y. Mori, T. Morita, and T. A. Matsuyama, "Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis," Clinical Science, vol. 133, no. 16, pp. 1779–1796, Aug. 2019. https://doi.org/10.1042/CS20190336.
C. Buechler, S. Feder, E. M. Haberl, and C. Aslanidis, "Chemerin isoforms and activity in obesity," International Journal of Molecular Sciences, vol. 20, no. 5, p. 1128, Mar. 2019. https://doi.org/10.3390/ijms20051128
J. Li, Y. Lu, N. Li, P. Li, Z. Wang, W. Ting, X. Liu, and W. Wu, "Chemerin: a potential regulator of inflammation and metabolism for chronic obstructive pulmonary disease and pulmonary rehabilitation," BioMed Research International, vol. 2020, no. 1, p. 4574509, 2020. https://doi.org/10.1155/2020/4574509.
B. Bondue, V. Wittamer, and M. Parmentier, "Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism," Cytokine & Growth Factor Reviews, vol. 22, no. 5–6, pp. 331–338, Oct. 2011. https://doi.org/10.1016/j.cytogfr.2011.11.004.
D. Rodríguez-Penas, S. Feijóo-Bandín, V. García-Rúa, A. Mosquera-Leal, D. Durán, A. Varela, M. Portolés, E. Roselló-Lletí, M. Rivera, C. Diéguez, and O. Gualillo, "The adipokine chemerin induces apoptosis in cardiomyocytes," Cellular Physiology and Biochemistry, vol. 37, no. 1, pp. 176–192, Aug. 2015. https://doi.org/10.1159/000430343.
D. J. Robinson and R. H. Christenson, "Creatine kinase and its CK-MB isoenzyme: the conventional marker for the diagnosis of acute myocardial infarction," The Journal of Emergency Medicine, vol. 17, no. 1, pp. 95-104, Jan. 1999. https://doi.org/10.1016/S0736-4679(98)00129-2
H. Sax, J. Contesse, P. Dubach, and W. H. Reinhart, "Creatine kinase MB during myocardial infarction: relationship to preexisting coronary heart disease and medication," Acta Cardiologica, vol. 52, no. 5, pp. 423-430, Jan. 1997. https://pubmed.ncbi.nlm.nih.gov/9428940/
W. Zhu et al., "Serum level of lactate dehydrogenase is associated with cardiovascular disease risk as determined by the Framingham risk score and arterial stiffness in a health-examined population in China," International Journal of General Medicine, vol. 11, pp. 11-17, Jan. 2022. https://doi.org/10.2147/IJGM.S337517
A. Farhana and S. L. Lappin, "Biochemistry, lactate dehydrogenase," in StatPearls, StatPearls Publishing, May 2023. https://www.ncbi.nlm.nih.gov/books/NBK557536/
H. Zhang et al., "High serum lactate dehydrogenase as a predictor of cardiac insufficiency at follow-up in elderly patients with acute myocardial infarction," Archives of Gerontology and Geriatrics, vol. 117, p. 105253, Feb. 2024. https://doi.org/10.1016/j.archger.2023.105253
E. G. Giannini, R. Testa, and V. Savarino, "Liver enzyme alteration: a guide for clinicians," CMAJ, vol. 172, no. 3, pp. 367-379, Feb. 2005. https://doi.org/10.1503/cmaj.1040752
D. S. Pratt and M. M. Kaplan, "Evaluation of abnormal liver-enzyme results in asymptomatic patients," New England Journal of Medicine, vol. 342, no. 17, pp. 1266-1271, Apr. 2000. https://doi.org/10.1056/NEJM200004273421707
A. M. Alvarez and D. Mukherjee, "Liver abnormalities in cardiac diseases and heart failure," International Journal of Angiology, vol. 20, no. 3, pp. 135-142, Sep. 2011. https://doi.org/10.1055/s-0031-1284434
Y. Chida, N. Sudo, Y. Motomura, and C. Kubo, "Electric foot-shock stress drives TNF-α production in the liver of IL-6-deficient mice," Neuroimmunomodulation, vol. 11, no. 6, pp. 419-424, Oct. 2004. https://doi.org/10.1159/000080153
J. Luo, H. Yang, and B. L. Song, "Mechanisms and regulation of cholesterol homeostasis," Nature Reviews Molecular Cell Biology, vol. 21, no. 4, pp. 225-245, Apr. 2020. https://doi.org/10.1038/s41580-019-0190-7
M. Ouimet, T. J. Barrett, and E. A. Fisher, "HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease," Circulation Research, vol. 124, no. 10, pp. 1505-1518, May 2019. https://doi.org/10.1161/CIRCRESAHA.119.312617
E. E. Al-Hadidi and W. M. Al-Obaidi, "Assessment of asprosin level and some physiological variables in patients with cardiovascular diseases in Kirkuk city, Iraq," Biomedicine, vol. 42, no. 5, pp. 973-977, Nov. 2022. https://doi.org/10.51248/.v42i5.1958
D. Zhang et al., "Important hormones regulating lipid metabolism," Molecules, vol. 27, no. 20, p. 7052, Oct. 2022. https://doi.org/10.3390/molecules27207052
H. Zheng, L. A. Sechi, E. P. Navarese, G. Casu, and G. Vidili, "Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review," Cardiovascular Diabetology, vol. 23, no. 1, p. 346, Sep. 2024. https://doi.org/10.1186/s12933-024-02434-5
S. T. Chiesa and M. Charakida, "High-density lipoprotein function and dysfunction in health and disease," Cardiovascular Drugs and Therapy, vol. 33, pp. 207-219, Apr. 2019. https://doi.org/10.1007/s10557-018-06846-w
S. Nazir et al., "Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!" Advanced Drug Delivery Reviews, vol. 159, pp. 94-119, Jan. 2020. https://doi.org/10.1016/j.addr.2020.10.006
A. Shuster, M. Patlas, J. H. Pinthus, and M. Mourtzakis, "The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis," The British Journal of Radiology, vol. 85, no. 1009, pp. 1-10, Jan. 2012. https://doi.org/10.1259/bjr/38447238
C. Boutari and C. S. Mantzoros, "A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on," Metabolism, vol. 133, p. 155217, Aug. 2022. https://doi.org/10.1016/j.metabol.2022.155217
A. H. Aziz, "Association of right ventricular infarction with inferior wall myocardial infarction," Kirkuk Journal of Medical Sciences, vol. 9, no. 1, pp. 101-157, Dec. 2021. https://doi.org/10.32894/kjms.2021.170173
Y. Msc, "Study the cardiac arrhythmia and disease among CCU patients in Kirkuk city hospitals (comparative study)," Bahrain Medical Bulletin, vol. 45, no. 1, Mar. 2023.
M. Poddar, Y. Chetty, and V. T. Chetty, "How does obesity affect the endocrine system? A narrative review," Clinical Obesity, vol. 7, no. 3, pp. 136-144, Jun. 2017. https://doi.org/10.1111/cob.12184
N. L. Benowitz and A. D. Burbank, "Cardiovascular toxicity of nicotine: implications for electronic cigarette use," Trends in Cardiovascular Medicine, vol. 26, no. 6, pp. 515-523, Aug. 2016. https://doi.org/10.1016/j.tcm.2016.03.001
W. Mohammed Ali, "What's new in cigarette smoking and hypertension?" Kirkuk Journal of Medical Sciences, vol. 12, no. 1, 2024. https://doi.org/10.32894/kjms.2024.147150.1098
M. Malenica et al., "Effect of cigarette smoking on haematological parameters in healthy population," Medical Archives, vol. 71, no. 2, pp. 132-136, Apr. 2017. https://doi.org/10.5455/medarh.2017.71.132-136